Carcinoma-associated fibroblasts provide operational flexibility in metastasis

Seminars in Cancer Biology

Volumn 25, Issue , 2014, Pages 33-46

  De Wever, Olivier ^a   Van Bockstal, Mieke ^a   Mareel, Marc ^a   Hendrix, An ^a   Bracke, Marc ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Carcinoma associated fibroblast; Ecosystem; Exosome; Invasion; Metastasis; Myofibroblast

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 7; OXALIPLATIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SCATTER FACTOR; SMAD2 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR MARKER;

ADIPOSE TISSUE; BIOPSY TECHNIQUE; BONE MARROW; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CARCINOGENESIS; CARCINOMA ASSOCIATED FIBROBLAST; CELL DIFFERENTIATION; CELL FUNCTION; CELL HETEROGENEITY; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; COLON CANCER; FIBROBLAST; HUMAN; INTRADUCTAL CARCINOMA; MESENCHYMAL STEM CELL; METASTASIS; METASTASIS POTENTIAL; MOLECULAR MECHANICS; MOUTH SQUAMOUS CELL CARCINOMA; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STEM CELL; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; CELL COMMUNICATION; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL COMMUNICATION; FIBROBLASTS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84897538576     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.12.009     Document Type: Review

References (174)

1. Yachida S., Jones S., Bozic I., Antal T., Leary R., Fu B., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
2. Campbell P.J., Yachida S., Mudie L.J., Stephens P.J., Pleasance E.D., Stebbings L.A., et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113.
3. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
4. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
5. Huijbers A., Tollenaar R.A., v Pelt G.W., Zeestraten E.C., Dutton S., McConkey C.C., et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol 2013, 24:179-185.
6. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008, 14:518-527.
7. de Kruijf E.M., Dekker T.J., Hawinkels L.J., Putter H., Smit V.T., Kroep J.R., et al. The prognostic role of TGF-beta signaling pathway in breast cancer patients. Ann Oncol 2013, 24:384-390.
8. Kadaba R., Birke H., Wang J., Hooper S., Andl C.D., Di Maggio F., et al. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J Pathol 2013, 230:107-117.
9. Erkan M., Michalski C.W., Rieder S., Reiser-Erkan C., Abiatari I., Kolb A., et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 2008, 6:1155-1161.
10. Tsujino T., Seshimo I., Yamamoto H., Ngan C.Y., Ezumi K., Takemasa I., et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res 2007, 13:2082-2090.
11. Yamashita M., Ogawa T., Zhang X., Hanamura N., Kashikura Y., Takamura M., et al. Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer 2012, 19:170-176.
12. Navab R., Strumpf D., Bandarchi B., Zhu C.Q., Pintilie M., Ramnarine V.R., et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A 2011, 108:7160-7165.
13. Farmer P., Bonnefoi H., Anderle P., Cameron D., Wirapati P., Becette V., et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009, 15:68-74.
14. De Wever O., Demetter P., Mareel M., Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008, 123:2229-2238.
15. De Wever O., Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003, 200:429-447.
16. Hinz B., Phan S.H., Thannickal V.J., Prunotto M., Desmouliere A., Varga J., et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012, 180:1340-1355.
17. Ostman A., Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev 2009, 19:67-73.
18. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013, 19:1423-1437.
19. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
20. Cardoso AP, Pinto ML, Pinto AT, Oliveira MI, Pinto MT, Goncalves R, et al. Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y, c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity. Oncogene. doi:10.1038/onc.2013.
21. San Francisco I.F., DeWolf W.C., Peehl D.M., Olumi A.F. Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer 2004, 112:213-218.
22. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
23. Rasanen K., Virtanen I., Salmenpera P., Grenman R., Vaheri A. Differences in the nemosis response of normal and cancer-associated fibroblasts from patients with oral squamous cell carcinoma. PLoS ONE 2009, 4:e6879.
24. Kiskowski M.A., Jackson R.S., Banerjee J., Li X., Kang M., Iturregui J.M., et al. Role for stromal heterogeneity in prostate tumorigenesis. Cancer Res 2011, 71:3459-3470.
25. Costea D.E., Hills A., Osman A.H., Thurlow J., Kalna G., Huang X., et al. Identification of two distinct carcinoma-associated fibroblast subtypes with differential tumor-promoting abilities in oral squamous cell carcinoma. Cancer Res 2013, 73:3888-3901.
26. Chaudhry S.I., Hooper S., Nye E., Williamson P., Harrington K., Sahai E. Autocrine IL-1beta-TRAF6 signalling promotes squamous cell carcinoma invasion through paracrine TNFalpha signalling to carcinoma-associated fibroblasts. Oncogene 2013, 32:747-758.
27. Denys H., Derycke L., Hendrix A., Westbroek W., Gheldof A., Narine K., et al. Differential impact of TGF-beta and EGF on fibroblast differentiation and invasion reciprocally promotes colon cancer cell invasion. Cancer Lett 2008, 266:263-274.
28. Wu X., Jin C., Wang F., Yu C., McKeehan W.L. Stromal cell heterogeneity in fibroblast growth factor-mediated stromal-epithelial cell cross-talk in premalignant prostate tumors. Cancer Res 2003, 63:4936-4944.
29. Herrera M., Islam A.B., Herrera A., Martin P., Garcia V., Silva J., et al. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin Cancer Res 2013, 19:5914-5926.
30. Reilly J.T., Nash J.R. Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue. J Clin Pathol 1988, 41:1269-1272.
31. Tanaka Y., Hirokawa M., Wakatsuki S., Sano T. Metastatic adenocarcinoma of the lymph node: peculiar desmoplasia mimicking intravenous metastasis. Histopathology 2002, 41:566-567.
32. Newman L.A., Pernick N.L., Adsay V., Carolin K.A., Philip P.A., Sipierski S., et al. Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann Surg Oncol 2003, 10:734-739.
33. Thariat J., Ahamad A., El-Naggar A.K., Williams M.D., Holsinger F.C., Glisson B.S., et al. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer 2008, 112:2698-2709.
34. Lehn C.N., Rapoport A. The desmoplastic lymph node reaction as a prognostic factor of cancer of the tongue and floor of the mouth. Sao Paulo Med J 1994, 112:591-596.
35. Hasebe T., Tsuda H., Hirohashi S., Shimosato Y., Tsubono Y., Yamamoto H., et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 1998, 49:195-208.
36. Okamoto T., Tsuburaya A., Kameda Y., Yoshikawa T., Cho H., Tsuchida K., et al. Prognostic value of extracapsular invasion and fibrotic focus in single lymph node metastasis of gastric cancer. Gastric Cancer 2008, 11:160-167.
37. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
38. Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15:35-44.
39. Zhao L., Lim S.Y., Gordon-Weeks A.N., Tapmeier T.T., Im J.H., Cao Y., et al. Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. Hepatology 2013, 57:829-839.
40. Calon A., Espinet E., Palomo-Ponce S., Tauriello D.V., Iglesias M., Cespedes M.V., et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 2012, 22:571-584.
41. Vidal-Vanaclocha F. The prometastatic microenvironment of the liver. Cancer Microenviron 2008, 1:113-129.
42. Van den Eynden G.G., Majeed A.W., Illemann M., Vermeulen P.B., Bird N.C., Hoyer-Hansen G., et al. The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res 2013, 73:2031-2043.
43. Stessels F., Van den Eynden G., Van der Auwera I., Salgado R., Van den Heuvel E., Harris A.L., et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer 2004, 90:1429-1436.
44. Momiyama M., Kumamoto T., Suetsugu A., Kishimoto H., Chishima T., Tanaka K., et al. Major liver resection stimulates stromal recruitment and metastasis compared with repeated minor resection. J Surg Res 2012, 178:280-287.
45. Duda D.G., Duyverman A.M., Kohno M., Snuderl M., Steller E.J., Fukumura D., et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A 2010, 107:21677-21682.
46. Campbell J.P., Karolak M.R., Ma Y., Perrien D.S., Masood-Campbell S.K., Penner N.L., et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol 2012, 10:e1001363.
47. Baglioni S., Francalanci M., Squecco R., Lombardi A., Cantini G., Angeli R., et al. Characterization of human adult stem-cell populations isolated from visceral and subcutaneous adipose tissue. FASEB J 2009, 23:3494-3505.
48. Quante M., Tu S.P., Tomita H., Gonda T., Wang S.S., Takashi S., et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011, 19:257-272.
49. Kidd S., Spaeth E., Watson K., Burks J., Lu H., Klopp A., et al. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLOS ONE 2012, 7:e30563.
50. Apte M.V., Wilson J.S., Lugea A., Pandol S.J. A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology 2013, 144:1210-1219.
51. Direkze N.C., Hodivala-Dilke K., Jeffery R., Hunt T., Poulsom R., Oukrif D., et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 2004, 64:8492-8495.
52. Puppa G., Maisonneuve P., Sonzogni A., Masullo M., Capelli P., Chilosi M., et al. Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging. Mod Pathol 2007, 20:843-855.
53. Yamaguchi J., Ohtani H., Nakamura K., Shimokawa I., Kanematsu T. Prognostic impact of marginal adipose tissue invasion in ductal carcinoma of the breast. Am J Clin Pathol 2008, 130:382-388.
54. Zhang Y., Daquinag A.C., Amaya-Manzanares F., Sirin O., Tseng C., Kolonin M.G. Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment. Cancer Res 2012, 72:5198-5208.
55. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J., Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002, 62:3603-3608.
56. Ishii G., Sangai T., Oda T., Aoyagi Y., Hasebe T., Kanomata N., et al. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem Biophys Res Commun 2003, 309:232-240.
57. Muehlberg F.L., Song Y.H., Krohn A., Pinilla S.P., Droll L.H., Leng X., et al. Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis 2009, 30:589-597.
58. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
59. Kidd S., Spaeth E., Dembinski J.L., Dietrich M., Watson K., Klopp A., et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009, 27:2614-2623.
60. Hutchinson L., Stenstrom B., Chen D., Piperdi B., Levey S., Lyle S., et al. Human Barrett's adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant. Stem Cells Dev 2011, 20:11-17.
61. Shinagawa K., Kitadai Y., Tanaka M., Sumida T., Kodama M., Higashi Y., et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 2010, 127:2323-2333.
62. Wang H., Cao F., De A., Cao Y., Contag C., Gambhir S.S., et al. Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells 2009, 27:1548-1558.
63. Chanda D., Isayeva T., Kumar S., Hensel J.A., Sawant A., Ramaswamy G., et al. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. Clin Cancer Res 2009, 15:7175-7185.
64. Kim S.W., Kim S.J., Park S.H., Yang H.G., Kang M.C., Choi Y.W., et al. Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK. Clin Cancer Res 2013, 19:415-427.
65. Chaturvedi P., Gilkes D.M., Wong C.C., Luo W., Zhang H., Wei H., et al. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest 2013, 123:189-205.
66. Jung Y., Kim J.K., Shiozawa Y., Wang J., Mishra A., Joseph J., et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun 2013, 4:1795.
67. Shibata W., Ariyama H., Westphalen C.B., Worthley D.L., Muthupalani S., Asfaha S., et al. Stromal cell-derived factor-1 overexpression induces gastric dysplasia through expansion of stromal myofibroblasts and epithelial progenitors. Gut 2013, 62:192-200.
68. Zhang Y., Yang P., Sun T., Li D., Xu X., Rui Y., et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol 2013, 15:284-294.
69. Fordyce C.A., Patten K.T., Fessenden T.B., Defilippis R., Hwang E.S., Zhao J., et al. Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes. Breast Cancer Res 2012, 14:R155.
70. McCaig C., Duval C., Hemers E., Steele I., Pritchard D.M., Przemeck S., et al. The role of matrix metalloproteinase-7 in redefining the gastric microenvironment in response to Helicobacter pylori. Gastroenterology 2006, 130:1754-1763.
71. Rajski M., Zanetti-Dallenbach R., Vogel B., Herrmann R., Rochlitz C., Buess M. IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC Med 2010, 8:1.
72. Duckworth C.A., Clyde D., Worthley D.L., Wang T.C., Varro A., Pritchard D.M. Progastrin-induced secretion of insulin-like growth factor 2 from colonic myofibroblasts stimulates colonic epithelial proliferation in mice. Gastroenterology 2013, 145:197-208.
73. Ostman A., Heldin C.H. PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007, 97:247-274.
74. Walter K., Omura N., Hong S.M., Griffith M., Vincent A., Borges M., et al. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin Cancer Res 2010, 16:1781-1789.
75. Saito R.A., Micke P., Paulsson J., Augsten M., Pena C., Jonsson P., et al. Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Res 2010, 70:2644-2654.
76. Calvo F., Ege N., Grande-Garcia A., Hooper S., Jenkins R.P., Chaudhry S.I., et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 2013, 15:637-646.
77. Macri L., Silverstein D., Clark R.A. Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drug Deliv Rev 2007, 59:1366-1381.
78. Hu M., Yao J., Cai L., Bachman K.E., van den Brule F., Velculescu V., et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005, 37:899-905.
79. Badiola I., Olaso E., Crende O., Friedman S.L., Vidal-Vanaclocha F. Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. Gut 2012, 61:1465-1472.
80. Liu C., Billadeau D.D., Abdelhakim H., Leof E., Kaibuchi K., Bernabeu C., et al. IQGAP1 suppresses TbetaRII-mediated myofibroblastic activation and metastatic growth in liver. J Clin Invest 2013, 123:1138-1156.
81. Mi Z., Bhattacharya S.D., Kim V.M., Guo H., Talbot L.J., Kuo P.C. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 2011, 32:477-487.
82. Mitra A.K., Zillhardt M., Hua Y., Tiwari P., Murmann A.E., Peter M.E., et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov 2012, 2:1100-1108.
83. Ko S.Y., Barengo N., Ladanyi A., Lee J.S., Marini F., Lengyel E., et al. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest 2012, 122:3603-3617.
84. Hendrix A., Hume A.N. Exosome signaling in mammary gland development and cancer. Int J Dev Biol 2011, 55:879-887.
85. Webber J., Steadman R., Mason M.D., Tabi Z., Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res 2010, 70:9621-9630.
86. Tang D.G., Conti C.J. Endothelial cell development, vasculogenesis, angiogenesis, and tumor neovascularization: an update. Semin Thromb Hemost 2004, 30:109-117.
87. Rana S., Malinowska K., Zoller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 2013, 15:281-295.
88. Peinado H., Aleckovic M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012, 18:883-891.
89. De Wever O., Pauwels P., De Craene B., Sabbah M., Emami S., Redeuilh G., et al. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 2008, 130:481-494.
90. De Craene B., Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013, 13:97-110.
91. Pena C., Cespedes M.V., Lindh M.B., Kiflemariam S., Mezheyeuski A., Edqvist P.H., et al. STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer Res 2013, 73:1287-1297.
92. Dumont N., Liu B., Defilippis R.A., Chang H., Rabban J.T., Karnezis A.N., et al. Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia 2013, 15:249-262.
93. Provenzano P.P., Eliceiri K.W., Campbell J.M., Inman D.R., White J.G., Keely P.J. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 2006, 4:38.
94. Conklin M.W., Eickhoff J.C., Riching K.M., Pehlke C.A., Eliceiri K.W., Provenzano P.P., et al. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol 2011, 178:1221-1232.
95. Shieh A.C., Rozansky H.A., Hinz B., Swartz M.A. Tumor cell invasion is promoted by interstitial flow-induced matrix priming by stromal fibroblasts. Cancer Res 2011, 71:790-800.
96. Barry-Hamilton V., Spangler R., Marshall D., McCauley S., Rodriguez H.M., Oyasu M., et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010, 16:1009-1017.
97. Erler J.T., Bennewith K.L., Nicolau M., Dornhofer N., Kong C., Le Q.T., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
98. Butcher D.T., Alliston T., Weaver V.M. A tense situation: forcing tumour progression. Nat Rev Cancer 2009, 9:108-122.
99. Yan X.L., Jia Y.L., Chen L., Zeng Q., Zhou J.N., Fu C.J., et al. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology 2013, 57:2274-2286.
100. De Boeck A., Pauwels P., Hensen K., Rummens J.L., Westbroek W., Hendrix A., et al. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut 2013, 62:550-560.
101. De Wever O., Nguyen Q.D., Van Hoorde L., Bracke M., Bruyneel E., Gespach C., et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 2004, 18:1016-1018.
102. Vermeulen L., De Sousa E.M.F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010, 12:468-476.
103. Henriksson M.L., Edin S., Dahlin A.M., Oldenborg P.A., Oberg A., Van Guelpen B., et al. Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion. Am J Pathol 2011, 178:1387-1394.
104. Liu R., Li J., Xie K., Zhang T., Lei Y., Chen Y., et al. FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res 2013, 73:5926-5935.
105. De Boeck A., Hendrix A., Maynard D., Van Bockstal M., Daniels A., Pauwels P., et al. Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. Proteomics 2013, 13:379-388.
106. Witkiewicz A.K., Freydin B., Chervoneva I., Potoczek M., Rizzo W., Rui H., et al. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther 2010, 10:391-396.
107. O'Connell J.T., Sugimoto H., Cooke V.G., MacDonald B.A., Mehta A.I., LeBleu V.S., et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A 2011, 108:16002-16007.
108. Hellevik T., Pettersen I., Berg V., Bruun J., Bartnes K., Busund L.T., et al. Changes in the secretory profile of NSCLC-associated fibroblasts after ablative radiotherapy: potential impact on angiogenesis and tumor growth. Transl Oncol 2013, 6:66-74.
109. Morikawa T., Baba Y., Yamauchi M., Kuchiba A., Nosho K., Shima K., et al. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 2011, 17:1452-1462.
110. Malanchi I., Santamaria-Martinez A., Susanto E., Peng H., Lehr H.A., Delaloye J.F., et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-89.
111. Saupe F., Schwenzer A., Jia Y., Gasser I., Spenle C., Langlois B., et al. Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model. Cell Rep 2013, 5:482-492.
112. Berdiel-Acer M., Bohem M.E., Lopez-Doriga A., Vidal A., Salazar R., Martinez-Iniesta M., et al. Hepatic carcinoma-associated fibroblasts promote an adaptative response in colorectal cancer cells that inhibit proliferation and apoptosis: nonresistant cells die by nonapoptotic cell death. Neoplasia 2011, 13:931-946.
113. Lin H.J., Zuo T., Lin C.H., Kuo C.T., Liyanarachchi S., Sun S., et al. Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells. Cancer Res 2008, 68:10257-10266.
114. Scott R.W., Hooper S., Crighton D., Li A., Konig I., Munro J., et al. LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J Cell Biol 2010, 191:169-185.
115. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 2007, 9:1392-1400.
116. Sanz-Moreno V., Gaggioli C., Yeo M., Albrengues J., Wallberg F., Viros A., et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 2011, 20:229-245.
117. Goetz J.G., Minguet S., Navarro-Lerida I., Lazcano J.J., Samaniego R., Calvo E., et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011, 146:148-163.
118. Simpkins S.A., Hanby A.M., Holliday D.L., Speirs V. Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol 2012, 227:490-498.
119. Kalra H., Simpson R.J., Ji H., Aikawa E., Altevogt P., Askenase P., et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol 2012, 10:e1001450.
120. Ji H., Erfani N., Tauro B.J., Kapp E.A., Zhu H.J., Moritz R.L., et al. Difference gel electrophoresis analysis of Ras-transformed fibroblast cell-derived exosomes. Electrophoresis 2008, 29:2660-2671.
121. Kim H.S., Choi D.Y., Yun S.J., Choi S.M., Kang J.W., Jung J.W., et al. Proteomic analysis of microvesicles derived from human mesenchymal stem cells. J Proteome Res 2012, 11:839-849.
122. Luga V., Zhang L., Viloria-Petit A.M., Ogunjimi A.A., Inanlou M.R., Chiu E., et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 2012, 151:1542-1556.
123. Walter N.D., Rice P.L., Redente E.F., Kauvar E.F., Lemond L., Aly T., et al. Wound healing after trauma may predispose to lung cancer metastasis: review of potential mechanisms. Am J Respir Cell Mol Biol 2011, 44:591-596.
124. Naumov G.N., Folkman J., Straume O. Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis 2009, 26:51-60.
125. Sleeman J.P. The metastatic niche and stromal progression. Cancer Metastasis Rev 2012, 31:429-440.
126. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196:395-406.
127. Aguirre-Ghiso J.A., Ossowski L., Rosenbaum S.K. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 2004, 64:7336-7345.
128. Lim P.K., Bliss S.A., Patel S.A., Taborga M., Dave M.A., Gregory L.A., et al. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res 2011, 71:1550-1560.
129. Mareel M., Oliveira M.J., Madani I. Cancer invasion and metastasis: interacting ecosystems. Virchows Arch 2009, 454:599-622.
130. Buijs J.T., Henriquez N.V., van Overveld P.G., van der Horst G., ten Dijke P., van der Pluijm G. TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis 2007, 24:609-617.
131. Barkan D., El Touny L.H., Michalowski A.M., Smith J.A., Chu I., Davis A.S., et al. Metastatic growth from dormant cells induced by a Col-I-enriched fibrotic environment. Cancer Res 2010, 70:5706-5716.
132. Cox T.R., Bird D., Baker A.M., Barker H.E., Ho M.W., Lang G., et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res 2013, 73:1721-1732.
133. Gao H., Chakraborty G., Lee-Lim A.P., Mo Q., Decker M., Vonica A., et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 2012, 150:764-779.
134. Chen H., Ko J.M., Wong V.C., Hyytiainen M., Keski-Oja J., Chua D., et al. LTBP-2 confers pleiotropic suppression and promotes dormancy in a growth factor permissive microenvironment in nasopharyngeal carcinoma. Cancer Lett 2012, 325:89-98.
135. McAllister S.S., Gifford A.M., Greiner A.L., Kelleher S.P., Saelzler M.P., Ince T.A., et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008, 133:994-1005.
136. Elkabets M., Gifford A.M., Scheel C., Nilsson B., Reinhardt F., Bray M.A., et al. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 2011, 121:784-799.
137. Castano Z., Marsh T., Tadipatri R., Kuznetsov H.S., Al-Shahrour F., Paktinat M., et al. Stromal EGF and IGF1 together modulate plasticity of disseminated triple negative breast tumors. Cancer Discov 2013, 3:922-935.
138. Pfeifer R., Darwiche S., Kohut L., Billiar T.R., Pape H.C. Cumulative effects of bone and soft tissue injury on systemic inflammation: a pilot study. Clin Orthop Relat Res 2013, 471:2815-2821.
139. Fodor D., Bondor C., Albu A., Simon S.P., Craciun A., Muntean L. The value of osteopontin in the assessment of bone mineral density status in postmenopausal women. J Invest Med 2013, 61:15-21.
140. Liu J., Xu K., Chase M., Ji Y., Logan J.K., Buchsbaum R.J. Tiam1-regulated osteopontin in senescent fibroblasts contributes to the migration and invasion of associated epithelial cells. J Cell Sci 2012, 125:376-386.
141. Klopp A.H., Spaeth E.L., Dembinski J.L., Woodward W.A., Munshi A., Meyn R.E., et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 2007, 67:11687-11695.
142. Zielske S.P., Livant D.L., Lawrence T.S. Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int J Radiat Oncol Biol Phys 2009, 75:843-853.
143. Madani I., De Neve W., Mareel M. Does ionizing radiation stimulate cancer invasion and metastasis?. Bull Cancer 2008, 95:292-300.
144. Ohuchida K., Mizumoto K., Murakami M., Qian L.W., Sato N., Nagai E., et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 2004, 64:3215-3222.
145. Huang Q., Li F., Liu X., Li W., Shi W., Liu F.F., et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 2011, 17:860-866.
146. Lotti F., Jarrar A.M., Pai R.K., Hitomi M., Lathia J., Mace A., et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med 2013, 210:2851-2872.
147. Starzynska T., Dabkowski K., Blogowski W., Zuba-Surma E., Budkowska M., Salata D., et al. An intensified systemic trafficking of bone marrow-derived stem/progenitor cells in patients with pancreatic cancer. J Cell Mol Med 2013, 17:792-799.
148. Bellows C.F., Zhang Y., Chen J., Frazier M.L., Kolonin M.G. Circulation of progenitor cells in obese and lean colorectal cancer patients. Cancer Epidemiol Biomarkers Prev 2011, 20:2461-2468.
149. + monocytes via CCL2. J Immunol 2013, 190:4861-4867.
150. De Broe M., Wieme R., Roels F. Letter: Membrane fragments with koinozymic properties released from villous adenoma of the rectum. Lancet 1975, 2:1214-1215.
151. De Broe M.E., Wieme R.J., Logghe G.N., Roels F. Spontaneous shedding of plasma membrane fragments by human cells in vivo and in vitro. Clin Chim Acta 1977, 81:237-245.
152. Suetsugu A., Honma K., Saji S., Moriwaki H., Ochiya T., Hoffman R.M. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug Deliv Rev 2013, 65:383-390.
153. Silva J., Garcia V., Rodriguez M., Compte M., Cisneros E., Veguillas P., et al. Analysis of exosome release and its prognostic value in human colorectal cancer. Genes Chromosomes Cancer 2012, 51:409-418.
154. Ge R., Tan E., Sharghi-Namini S., Asada H.H. Exosomes in cancer microenvironment and beyond: have we overlooked these extracellular messengers?. Cancer Microenviron 2012, 5:323-332.
155. Bryant R.J., Pawlowski T., Catto J.W., Marsden G., Vessella R.L., Rhees B., et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012, 106:768-774.
156. Taylor D.D., Atay S., Metzinger D.S., Gercel-Taylor C. Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components. Gynecol Oncol 2010, 116:213-221.
157. Palazzolo G., Albanese N.N., DI Cara G., Gygax D., Vittorelli M.L., Pucci-Minafra I. Proteomic analysis of exosome-like vesicles derived from breast cancer cells. Anticancer Res 2012, 32:847-860.
158. Gallo A., Alevizos I. Isolation of circulating microRNA in saliva. Methods Mol Biol 2013, 1024:183-190.
159. Lacroix R., Judicone C., Mooberry M., Boucekine M., Key N.S., Dignat-George F. Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2013, 10.1111/jth.12207.
160. Rupp A.K., Rupp C., Keller S., Brase J.C., Ehehalt R., Fogel M., et al. Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage. Gynecol Oncol 2011, 122:437-446.
161. Gercel-Taylor C., Atay S., Tullis R.H., Kesimer M., Taylor D.D. Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer patients. Anal Biochem 2012, 428:44-53.
162. Grau A.M., Wen W., Ramroopsingh D.S., Gao Y.T., Zi J., Cai Q., et al. Circulating transforming growth factor-beta-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 2008, 112:335-341.
163. Divella R., Daniele A., Savino E., Palma F., Bellizzi A., Giotta F., et al. Circulating levels of transforming growth factor-betaeta (TGF-beta) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer. Anticancer Res 2013, 33:1491-1497.
164. Panis C., Herrera A.C., Victorino V.J., Aranome A.M., Cecchini R. Screening of circulating TGF-beta levels and its clinicopathological significance in human breast cancer. Anticancer Res 2013, 33:737-742.
165. Zhao L., Ji W., Zhang L., Ou G., Feng Q., Zhou Z., et al. Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer. J Thorac Oncol 2010, 5:521-525.
166. Du Y.Z., Gu X.H., Li L., Gao F. The diagnostic value of circulating stanniocalcin-1 mRNA in non-small cell lung cancer. J Surg Oncol 2011, 104:836-840.
167. Jensen B.V., Johansen J.S., Skovsgaard T., Brandt J., Teisner B. Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer. Int J Cancer 2002, 98:582-589.
168. Palma M.A., Body J.J. Usefulness of bone formation markers in breast cancer. Int J Biol Markers 2005, 20:146-155.
169. Zissimopoulos A., Stellos K., Matthaios D., Petrakis G., Parmenopoulou V., Babatsikou F., et al. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. J BUON 2009, 14:463-472.
170. Ohlund D., Lundin C., Ardnor B., Oman M., Naredi P., Sund M. Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br J Cancer 2009, 101:91-97.
171. Nystrom H., Naredi P., Hafstrom L., Sund M. Type IV collagen as a tumour marker for colorectal liver metastases. Eur J Surg Oncol 2011, 37:611-617.
172. Kang C.Y., Wang J., Axell-House D., Soni P., Chu M.L., Chipitsyna G., et al. Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma. J Gastrointest Surg 2013, 18:7-15.
173. Perrotta R., Bevelacqua Y., Malaguarnera G., Paladina I., Giordano M., Malaguarnera M. Serum markers of cutaneous melanoma. Front Biosci (Elite Ed) 2010, 2:1115-1122.
174. Bertotti A., Migliardi G., Galimi F., Sassi F., Torti D., Isella C., et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011, 1:508-523.